Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells, and MHC class II.
about
Transplantation tolerance and its outcome during infections and inflammationImmuno-intervention for the induction of transplantation tolerance through mixed chimerismLinear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunityAllospecific rejection of MHC class I-deficient bone marrow by CD8 T cells.LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.Recipient dendritic cells, but not B cells, are required antigen-presenting cells for peripheral alloreactive CD8+ T-cell tolerance.Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathwayHematopoietic chimerism and transplantation tolerance: a role for regulatory T cells.Longitudinal studies of a B cell-derived signature of tolerance in renal transplant recipientsAdoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.Hematopoietic cell transplantation for tolerance induction: animal models to clinical trialsOld game, new players: Linking classical theories to new trends in transplant immunology.Transplantation tolerance through mixed chimerism.Experimental models of B cell tolerance in transplantation.Induction of tolerance through mixed chimerism.Induction of transplantation tolerance through regulatory cells: from mice to men.B cells with immune-regulating function in transplantation.Hematopoietic stem cell infusion/transplantation for induction of allograft tolerance.Layers of regulation in induction of mixed chimerism by anti-CD40L.Mechanisms of transplantation tolerance in animals and humans.Rapamycin and CTLA4Ig synergize to induce stable mixed chimerism without the need for CD40 blockade.
P2860
Q26829817-9B08E23E-5D80-4960-BAE4-12359E4E65C7Q27001243-39A3CA30-F602-4BA9-B7B1-025A797B4BEAQ33614657-B362136F-A3D9-4A3A-8832-BC5B0E7FB359Q33709427-C8DF4297-220A-4CAD-B128-17EACEEC043DQ34172252-B3242482-7FBB-4268-9C87-006316177178Q34433840-77C97ECA-F377-438F-90E3-6084DEFC6E00Q34593527-8D8AA898-126A-4226-96B3-EBB8EF2F474EQ35928393-F859C1DF-A068-44AB-B232-781C147AA61BQ36498594-45124840-92D6-491E-8E86-4F6A0EC383FFQ37002020-8D40A0AB-69D3-4CA5-9BAD-25BEBCC1EEC1Q37157989-D65E49BE-7666-4C32-B242-8085D5CD94FCQ37388414-B420DF08-3044-4682-A56E-FC583F6219E3Q37662989-C93B0D6F-6402-4332-A221-A2EABD48AB90Q37784380-6545B574-1A76-4416-BDC5-D0D6464D5E73Q37934146-0050604F-C2C0-43E0-97BA-8A77CA641B57Q38175306-49E08A4E-5D57-49C1-8119-8963FD06D87FQ38187170-F627FB16-104D-4A63-A98E-3813BAF421CBQ38213294-C9C257DD-523E-4D2B-9DEF-CC688AB9BC41Q38309290-C7FC52DC-63DB-4491-BE55-1636ECFEA204Q42083190-489C5214-D153-414D-AFD3-885BCC995CC6Q42699024-845927C3-BD48-4D00-94E3-EC2F90707A1DQ54283965-BD7B9241-B574-4B46-9E47-E98FC49BD7A3
P2860
Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells, and MHC class II.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Alloreactive CD8 T cell tolera ...... ritic cells, and MHC class II.
@en
Alloreactive CD8 T cell tolera ...... ritic cells, and MHC class II.
@nl
type
label
Alloreactive CD8 T cell tolera ...... ritic cells, and MHC class II.
@en
Alloreactive CD8 T cell tolera ...... ritic cells, and MHC class II.
@nl
prefLabel
Alloreactive CD8 T cell tolera ...... ritic cells, and MHC class II.
@en
Alloreactive CD8 T cell tolera ...... ritic cells, and MHC class II.
@nl
P2093
P2860
P1476
Alloreactive CD8 T cell tolera ...... ritic cells, and MHC class II.
@en
P2093
Fabienne Haspot
Joshua Mollov
Megan Sykes
Meredith Chittenden
Thomas Fehr
Timothy Hogan
P2860
P304
P356
10.4049/JIMMUNOL.181.1.165
P407
P577
2008-07-01T00:00:00Z